However, the different sites of action of the above 2 therapeutic drugs are as follows: the main work site of CA4P was in the extracellular matrix (ECM), which was used to block the neovascularization of tumor tissues, while V9302 normally binds to the intracellular transmembrane protein ASCT2 to block glutamine [30,31]. This evidence concerns the gene SLC1A5 and neoplasm.